Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Capivasertib API

Product
  • Categoría Terapéutica Oncology

  • Número CAS

    1143532‑39‑1

  • Tecnología del API

    Small‑molecule synthetic API

  • Forma de Dosificación

    Tabletas

  • Estado de Desarrollo en Dr. Reddy’s

    En desarrollo

Mechanism of action

Capivasertib inhibits all three AKT isoforms (AKT1, AKT2, AKT3).
AKT is a central signaling node in the PI3K/AKT/mTOR pathway, regulating cell proliferation, survival, and metabolism.
By blocking AKT kinase activity, capivasertib:

Inhibits phosphorylation of downstream AKT substrates
Suppresses tumor cell growth and survival
Overcomes resistance to endocrine therapy driven by PIK3CA mutations, AKT1 mutations, or PTEN loss


Demonstrates antitumor activity both as monotherapy and in combination with endocrine agents.

Indication

"Approved indication (FDA):

In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)‑positive, HER2‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following disease progression on endocrine therapy." 
 

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Bortezomib

Anti-Cáncer / Oncologico

arrow

Cabazitaxel

Anti-Cáncer / Oncologico

arrow

Cabozantinib S-Malate

Anti-Cáncer / Oncologico

arrow

Capecitabina

Anti-Cáncer / Oncologico

arrow

Carfilzomib

Anti-Cáncer / Oncologico

arrow

Decitabina

Anti-Cáncer / Oncologico

arrow

Deucravacitinib

Anti-Cáncer / Oncologico

arrow

Mesilato De Eribulina

Anti-Cáncer / Oncologico

arrow

Acetato De Abiraterona

Anti-Cáncer / Oncologico

arrow

Apalutamide (Amorphous & Form B)

Anti-Cáncer / Oncologico

arrow

Azacitidina

Anti-Cáncer / Oncologico

arrow

Cabozantinib HCl

Anti-Cáncer / Oncologico

arrow

Clorhidrato De Bendamustina

Anti-Cáncer / Oncologico

arrow

Descargo de responsabilidad

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.